Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/23/20
End: 06/01/27
Due: 06/01/28
Phase: N/A
Priority: Normal
Start: 10/29/24
End: 08/01/38
Due: 08/01/39
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | NCT04448886 | Ana C Garrido-Castro, MD | user2@example.com | None | 2020-09-23 | 2027-06-01 | 2028-06-01 | - | - | 2025-07-14 |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | NCT06533826 | Ana C Garrido-Castro, MD | user2@example.com | None | 2024-10-29 | 2038-08-01 | 2039-08-01 | - | - | 2025-07-14 |